Figure 6.

Mutations within the IPO5 binding region of FLIL33 result in protein degradation. A, whole cell lysates from NHLFs transfected with plasmids encoding WT FLIL33HA, FLIL33(46/56A₁₁), or FLIL33(61/67A₇), with or without IPO5 attenuation by IPO5-targeting siRNA, were analyzed by Western blot. B, Whole cell lysates of NHLFs transfected with plasmid encoding FLIL33(46/56A₁₁) and IPO5-targeting siRNA, with or without bortezomib were analyzed by Western blot. C, NHLFs transfected with plasmids encoding FLIL33(46/56A₁₁) or FLIL33(61/67A₇) were treated with cycloheximide, and lysates were collected at the time points indicated. Western blot was performed and probed with anti-HA antibody at indicated times (h). The experiments were performed in NHLFs from at least two different donors with consistent results.